140 related articles for article (PubMed ID: 37937484)
1. Safety and efficacy of peptide receptor radionuclide therapy in patients with advanced pheochromocytoma and paraganglioma: A single-institution experience and review of the literature.
Tang CYL; Chua WM; Huang HL; Lam WW; Loh LM; Tai D; Ong SYK; Yan SX; Loke KSH; Ng DC; Tham WY
J Neuroendocrinol; 2023 Dec; 35(12):e13349. PubMed ID: 37937484
[TBL] [Abstract][Full Text] [Related]
2. Peptide receptor radionuclide therapy in patients with metastatic progressive pheochromocytoma and paraganglioma: long-term toxicity, efficacy and prognostic biomarker data of phase II clinical trials.
Severi S; Bongiovanni A; Ferrara M; Nicolini S; Di Mauro F; Sansovini M; Lolli I; Tardelli E; Cittanti C; Di Iorio V; Mezzenga E; Scarpi E; Ibrahim T; Paganelli G; Zovato S
ESMO Open; 2021 Aug; 6(4):100171. PubMed ID: 34139487
[TBL] [Abstract][Full Text] [Related]
3. Peptide receptor radionuclide therapy with 177Lu- or 90Y-SSTR peptides in malignant pheochromocytomas (PCCs) and paragangliomas (PGLs): results from a single institutional retrospective analysis.
Rubino M; Di Stasio GD; Bodei L; Papi S; Rocca PA; Ferrari ME; Fodor CI; Bagnardi V; Frassoni S; Mei R; Fazio N; Ceci F; Grana CM
Endocrine; 2024 May; 84(2):704-710. PubMed ID: 38324106
[TBL] [Abstract][Full Text] [Related]
4.
Parghane RV; Talole S; Basu S
Ann Nucl Med; 2021 Jan; 35(1):92-101. PubMed ID: 33135123
[TBL] [Abstract][Full Text] [Related]
5. Treatment of inoperable or metastatic paragangliomas and pheochromocytomas with peptide receptor radionuclide therapy using 177Lu-DOTATATE.
Zandee WT; Feelders RA; Smit Duijzentkunst DA; Hofland J; Metselaar RM; Oldenburg RA; van Linge A; Kam BLR; Teunissen JJM; Korpershoek E; Hendriks JM; Abusaris H; Slagter C; Franssen GJH; Brabander T; De Herder WW
Eur J Endocrinol; 2019 Jul; 181(1):45-53. PubMed ID: 31067510
[TBL] [Abstract][Full Text] [Related]
6. 177Lu-DOTATATE therapy in metastatic/inoperable pheochromocytoma-paraganglioma.
Jaiswal SK; Sarathi V; Memon SS; Garg R; Malhotra G; Verma P; Shah R; Sehemby MK; Patil VA; Jadhav S; Lila AR; Shah NS; Bandgar TR
Endocr Connect; 2020 Oct; 9(9):864-873. PubMed ID: 32784267
[TBL] [Abstract][Full Text] [Related]
7. Peptide Receptor Radionuclide Therapy as a Novel Treatment for Metastatic and Invasive Phaeochromocytoma and Paraganglioma.
Mak IYF; Hayes AR; Khoo B; Grossman A
Neuroendocrinology; 2019; 109(4):287-298. PubMed ID: 30856620
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of [
Mitjavila M; Jimenez-Fonseca P; Belló P; Pubul V; Percovich JC; Garcia-Burillo A; Hernando J; Arbizu J; Rodeño E; Estorch M; Llana B; Castellón M; García-Cañamaque L; Gajate P; Riesco MC; Miguel MB; Balaguer-Muñoz D; Custodio A; Cano JM; Repetto A; Garcia-Alonso P; Muros MA; Vercher-Conejero JL; Carmona-Bayonas A
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(8):2486-2500. PubMed ID: 36877234
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma.
Kong G; Grozinsky-Glasberg S; Hofman MS; Callahan J; Meirovitz A; Maimon O; Pattison DA; Gross DJ; Hicks RJ
J Clin Endocrinol Metab; 2017 Sep; 102(9):3278-3287. PubMed ID: 28605448
[TBL] [Abstract][Full Text] [Related]
10. Response to targeted radionuclide therapy with [
Prado-Wohlwend S; Del Olmo-García MI; Bello-Arques P; Merino-Torres JF
Front Endocrinol (Lausanne); 2022; 13():957172. PubMed ID: 36339441
[TBL] [Abstract][Full Text] [Related]
11. Effects of Peptide Receptor Radiotherapy in Patients with Advanced Paraganglioma and Pheochromocytoma: A Nation-Wide Cohort Study.
Kornerup LS; Andreassen M; Knigge U; Arveschoug AK; Poulsen PL; Kjær A; Oturai PS; Grønbæk H; Dam G
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38611027
[TBL] [Abstract][Full Text] [Related]
12. 'Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: A systematic review and meta-analysis'.
Satapathy S; Mittal BR; Bhansali A
Clin Endocrinol (Oxf); 2019 Dec; 91(6):718-727. PubMed ID: 31569282
[TBL] [Abstract][Full Text] [Related]
13. Clinical utility of
Parghane RV; Naik C; Talole S; Desmukh A; Chaukar D; Banerjee S; Basu S
Head Neck; 2020 Mar; 42(3):401-416. PubMed ID: 31755622
[TBL] [Abstract][Full Text] [Related]
14. A Clinical Efficacy of PRRT in Patients with Advanced, Nonresectable, Paraganglioma-Pheochromocytoma, Related to SDHx Gene Mutation.
Kolasinska-Ćwikła A; Pęczkowska M; Ćwikła JB; Michałowska I; Pałucki JM; Bodei L; Lewczuk-Myślicka A; Januszewicz A
J Clin Med; 2019 Jun; 8(7):. PubMed ID: 31262070
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcome of indigenous
Sitani K; Parghane RV; Talole S; Basu S
Br J Radiol; 2021 Jan; 94(1117):20201041. PubMed ID: 33095671
[TBL] [Abstract][Full Text] [Related]
16. Peptide Receptor Radionuclide Treatment and (131)I-MIBG in the management of patients with metastatic/progressive phaeochromocytomas and paragangliomas.
Nastos K; Cheung VTF; Toumpanakis C; Navalkissoor S; Quigley AM; Caplin M; Khoo B
J Surg Oncol; 2017 Mar; 115(4):425-434. PubMed ID: 28166370
[TBL] [Abstract][Full Text] [Related]
17. Peptide Receptor Radionuclide Therapy in Patients With Advanced Progressive Medullary Thyroid Cancer: Efficacy, Safety, and Survival Predictors.
Liu Q; Kulkarni HR; Zhao T; Schuchardt C; Chen X; Zhu Z; Zhang J; Baum RP
Clin Nucl Med; 2023 Mar; 48(3):221-227. PubMed ID: 36723881
[TBL] [Abstract][Full Text] [Related]
18. 131I-metaiodobenzylguanidine and peptide receptor radionuclide therapy in pheochromocytoma and paraganglioma.
Jungels C; Karfis I
Curr Opin Oncol; 2021 Jan; 33(1):33-39. PubMed ID: 33093336
[TBL] [Abstract][Full Text] [Related]
19. Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE.
Parghane RV; Talole S; Prabhash K; Basu S
Clin Nucl Med; 2017 Jun; 42(6):428-435. PubMed ID: 28319500
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of High-Specific-Activity
Pryma DA; Chin BB; Noto RB; Dillon JS; Perkins S; Solnes L; Kostakoglu L; Serafini AN; Pampaloni MH; Jensen J; Armor T; Lin T; White T; Stambler N; Apfel S; DiPippo VA; Mahmood S; Wong V; Jimenez C
J Nucl Med; 2019 May; 60(5):623-630. PubMed ID: 30291194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]